Biosimilar Retacrit™ (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
The purpose of this study is to observe correction of haemoglobin (Hb) levels in patients receiving chemotherapy as a consequence of a solid tumour, a malignant lymphoma or a multiple myeloma and who are treated with Retacrit™.
Chemotherapy-induced Symptomatic Anaemia|Solid Tumours|Malignant Lymphomas|Multiple Myeloma
Change and corrected Hemoglobin levels, Participants who have hemoglobin values between 11 and 12 g/dl after 6 months of treatment., 6 months
Observation of blood value development, Observation of blood value development: hemoglobin, hematocrit, reticulocytes, serum iron, ferritin, transferrin saturation, 6 months|Evaluation of the profiles of treated patients, 6 months|Evaluation of prescriber's therapy plan, 6 months|Evaluation of the correlation between the therapy plans of prescribing oncologists and patient characteristics, 6 months|Observation of the tolerability profile of Epoetin Zeta, 6 months
This is a non-interventional, descriptive, national, multi-site, longitudinal and prospective observational study in adult patients who are suffering from cancer or malignant blood disease and whose chemotherapy treatment has induced symptomatic anaemia and being treated with Retacrit® to correct haemoglobin levels.